A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation
← catalyst calendarSponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
1,005actual
Sites
60
Countries
Puerto Rico, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-03-13 | actual | When the study began enrolling |
| Primary completion | 2026-05-06 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-10-30 | estimated | The whole study's end, after follow-up |
| First posted | 2024-03-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Obesity
Interventions
- Drug: Trevogrumab-Part A — also filed as REGN1033, GDF8
- Drug: Trevogrumab-Part B and Part C — also filed as REGN1033, GDF8
- Drug: Garetosmab — also filed as REGN2477, Activin A
- Drug: Semaglutide — also filed as Wegovy®
- Drug: Matching Placebo-Part A
- Drug: Matching Placebo-Trevogrumab
- Drug: Matching Placebo-Garetosmab
Primary outcomes
what the primary-completion date above is the date OFIncidence of treatment-emergent adverse events (TEAEs)
measured Baseline to week 7
Severity of TEAEs
measured Baseline to week 7
Percent change in total fat mass
measured Baseline to week 26
Percent change in total lean mass
measured Baseline to week 26
Percent change in body weight
measured Baseline to week 26
Percent change in total fat mass
measured Baseline to week 52
Percent change in total lean mass
measured Baseline to week 52
Percent change in body weight
measured Baseline to week 52
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed